An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study

Table 4 Change in Acute and Preventive Treatments Between Visits^a

	Preventive Treatment			Acute Treatment
	FU 1	FU 5	FU Last	FU 1	FU 5	FU Last
Patients with any changes, n (%)^b	54 (8.9)	30 (7.9)	42 (6.9)	71 (11.7)	12 (3.2)	22 (3.6)
Number of treatments changed, n	70	42	58	119	19	36
Started, n (%)^c	30 (42.9)	27 (64.3)	32 (55.2)	50 (42.0)	5 (26.3)	18 (50.0)
Discontinued, n (%)^c	25 (35.7)	10 (23.8)	16 (27.6)	21 (17.6)	2 (10.5)	14 (38.9)
Dose decreased, n (%)^c	11 (15.7)	2 (4.8)	6 (10.3)	64 (53.8)	5 (26.3)	8 (22.2)
Dose increased, n (%)^c	12 (17.1)	6 (14.3)	9 (15.5)	5 (4.2)	7 (36.8)	4 (11.1)

FU = follow-up visit; any visit after baseline regardless of whether onabotulinumtoxinA was administered
^aChange reflects the change between the visit indicated and the visit immediately prior
^bPercentage is based on the number of patients presenting at the follow-up visit
^cPercentage is based on the number of medications that were changed since the previous visit. A given treatment change may be associated with 1 or more subcategory (started, discontinued, dose decreased, dose increased)

ISSN: 1129-2377